# A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India

> **NCT07157423** · PHASE4 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 64 (estimated)

## Conditions studied

- Severe Postpartum Haemorrhage

## Interventions

- **DRUG:** Eptacog alfa (NovoSeven)

## Key facts

- **NCT ID:** NCT07157423
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-26
- **Primary completion:** 2027-03-26
- **Final completion:** 2027-03-26
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07157423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07157423, "A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07157423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*